Nuplex : Update on Scheme timing & FY16 earnings

Microsoft Word - Nuplex US reg process complete 4 May 2016

NZX/ASX release 4 May 2016

US anti-trust regulatory process successfully completed

Nuplex Industries Limited (NZX/ASX: NPX) today advises that the anti-trust regulatory review process in the United States of America has been successfully concluded in relation to the proposed acquisition of Nuplex by Allnex Belgium SA/NV (Allnex) by way of scheme of arrangement. This completes the anti-trust regulatory review of the proposed transaction in the United States.

The process to obtain the necessary regulatory approvals in all remaining jurisdictions continues.

Nuplex notes there is no change to the indicative timetable previously advised and repeated below in Appendix 1.

More information on the proposed scheme of arrangement is available via Nuplex's Investor Centre at www.nuplex.com.

Ends

For more information please contact;

Josie Ashton, Director Corporate Communications

[phone]

[e-mail]

APPENDIX 1- Indicative timetable

The following is an indicative timetable, setting out the relevant dates in the event that the regulatory approvals are able to be obtained by mid-July.

These dates are subject to change. References to timing are indicative only and will be dependent on the receipt of regulatory approvals, which are outside of both parties' control. Nuplex will advise shareholders if these dates are to change substantially.

Event	Indicative timing
Allnex/Advent provide notice to Nuplex that all regulatory approvals are expected to be received within 6 weeks	Early June 2016
First Court Date	Early July 2016
Notice of Meeting and Scheme Booklet dispatched to Nuplex shareholders	Mid July 2016
Special Meeting to vote on the Scheme	Early August 2016
Second Court Date	Mid August 2016
Implementation & Payment Date	End August 2016
The final date the Scheme can be implemented unless agreed by the parties	9 November 2016

About Nuplex

Nuplex is a leading, global manufacturer of resins used in paints, coatings and structural materials with annual sales of c.NZ$1.5 billion (c.US$1 billion). Listed on the NZX and the ASX, Nuplex is a global leader in rheology control coatings technology, as well as performance and industrial coating resins, particularly for Automotive OEM, Vehicle Re-finish, Wood, and Protective coatings. From its 16 production sites located across Asia, Europe, America and Australia and New Zealand, Nuplex has customers in over 80 countries worldwide. Through its global R&D network of local technical service support, regional R&D centers and a dedicated Innovation Centre in The Netherlands, Nuplex works in partnership with its customers to develop the right solution for their coatings challenges.

About Allnex

Allnex, formerly Cytec Industries' Coating Resins business and acquired by Advent in 2013 for US$1.15 billion, with sales of c. US$1.5 billion, is a leading global producer of coating resins and additives for architectural, industrial, protective, automotive and special purpose coatings and inks. Allnex is recognized as a specialty chemicals pioneer and offers an extensive range of products including innovative liquid resins & additives, radiation cured and powder coating resins & additives and cross linkers for use on wood, metal, plastic, and other surfaces. Today, Allnex has EBITDA of about US$220 million and has a strong global presence with 17 manufacturing sites and 12 research & technology support facilities throughout the world, focusing on assisting its c.3,000 customers to rapidly bring advanced coating solutions to market.

About Advent International

Founded in 1984, Advent International is one of the largest and most experienced global private equity firms and a leading investor in the global Chemicals industry. Advent's investment philosophy is centred around supporting leading management teams and providing resources for further growth, in order to execute on a mutually developed strategy and investment case. To date, Advent has raised cumulative capital of c.US$40 billion, and has executed over 310 transactions including over 30 investments in the Chemicals industry. Advent has a strong track record of making significant and successful investments, with recent chemicals transactions including Allnex (formerly Cytec Industries' Coating Resins business), Oxea, Maxam and Grupo Transmerquim. Advent also has extensive experience in conducting Public-to-Private transactions, with recent examples including Douglas, Mediq and Unit 4.

2